Clinical Trial Update: A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) [Phase 2, Phase 3]

View source ↗

Summary

Recruiting update for MK-0616 (Enlicitide Decanoate), an oral PCSK9 inhibitor, studied in children and adolescents with heterozygous familial hypercholesterolem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterozygous Familial Hypercholesterolemia

Drugs mentioned

• Enlicitide Decanoate (Enlicitide Decanoate)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 2, Phase 3 | Status: RECRUITING